Gene patent ruling hurts Myriad, but not fatally
The Supreme Court's decision cuts both ways for the biotech company that had patented the genes thought to cause breast cancer.
You can, however, hold exclusive rights to any Frankensteined gene that comes out of your lab. That's the leeway the Supreme Court offered on Thursday when it handed down its decision in Association for Molecular Pathology vs. Myriad Genetics (MYGN), which centered around Myriad's desire to patent the so-called BRCA genes believed to cause breast cancer.
This is going to create quite a mess in the federal patent office, where thousands of patents for isolated genes have been issued since 1982. It's not great news for biotech companies, either, as those 30-plus years of patents helped protect their research from competitors and, in turn, attracted a lot of investment.
On the other side of the equation, according to Bloomberg, it frees doctor groups and patient advocates to use those genes for clinical testing and research that they accused Myriad of blocking. According to Justice Clarence Thomas' written decision against Myriad, you have to actually make something to patent it. While identifying and isolating an existing gene is a "groundbreaking, innovative, or even brilliant discovery," it's not an invention and doesn't warrant patent protection.
The decision unwinds that of the Federal Court of Appeals, which determined that separating the gene from the surrounding natural chromosome by cutting the chemicals between them creates complementary DNA, or cDNA. But with the Supreme Court ruling, natural material no longer qualifies as cDNA, and only modified synthetic sequences can be patented as cDNA.
Myriad still got some good news, however, because the processes for isolating genes in naturally occurring DNA and applying them to treatments are still patent-protected. That's a win for company, analysts say, because it gets to keep the 24 patents on its tests for hereditary breast and ovarian cancer risk. One of those tests identified a genetic mutation in Angelina Jolie and led the actress to undergo a double mastectomy.
With Myriad's and other companies' patented genes now freed, gene databases are available for the production of new analytical technology and treatments. Annual U.S. spending on medical DNA testing will rise to $25 billion in the next decade from $5 billion in 2010, according to UnitedHealth Group (UNH), the biggest for-profit health insurer in the nation.
Maybe Henrietta Lacks descendants will be able to get some reparations from the sneaky theft of her
immortal cells that all humankind has benefitted from since her death in 1951. Scientists have grown
about 20 tons of her cells and there are almost 11,000 patents using her cells. While it's nice they named
a school after her and gave her an honorary degree 60 years after her death and a day set aside I her honor
Oct, 11th. and a Dr. bought a grave marker 60 years after her death. Not one organization that I know of
ever offered to give her family one cent. An author, Rebecca Skloot started a foundation using some of the
proceeds from her book, that paid to repair son Davids tractor trailer and helps with education grants.. But,
Johns Hopkins where his mothers immortal genes were first discovered and grown is still sending him bill for
$125,000.00 for heart surgery. That he's paying off a little by little every month.
We're talking polio vaccine and a lot of other medicines like chemotherapy drugs, companies
have made billions from...if not trillions from by now. They are still growing and using HeLa cells. There are
still two of her sons living. Even if they were awarded a mere $2000.00 for every patent issued it would mean
that her sons could have a secure retirement and David would be able to pay off his hospital bill to Johns
Hopkins and spend the rest of his days in peace instead of worrying about how to pay next months bill to the
hospital that benefitted astronomically from his mothers contribution to medicine.
I really hope that in the future all Cancer can be cured, I lost my own Mom to cancer.
If there were more research on health issues instead of wars there would be more Birthdays.
Not on the side of these companies that want to suck the life out of progress.
What if Columbus had been able to extort a fee from all who traveled to the new world.
What if Einstein had said you cannot study or research my theories unless you pay me first.
This does have its upside and down side, both in gene research and testing, and in application for gene manipulation. Since lesser known and small genetic engineering firms will be open to exploit genetic discoveries, we may see some genetic garbage and even some dangerous gene's hit our lives...Imagine all the small biotech firms who have poorly trained technicians developing synthetic genes or retro gene viruses. We could see come very dangerous mutant genes come out of small labs.
I guess genetic manipulation will be a crap shoot, either creating an environment of massive breakthroughs or possibly the end of humanity. Or at least a race of genetic mutants who cannibalistically eat the rest of us in their question for domination of the world.
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
[BRIEFING.COM] Stocks remain near their recent levels with the S&P 500 trading within eight points of the 2,000 mark. In our midday update, we mentioned the relative weakness of the Russell 2000, but the small-cap index has since climbed to a new session high and is now up 0.2%.
Elsewhere, the Nasdaq Composite (unch) continues trailing the broader market as biotech and chipmaker shares lag. The iShares Nasdaq Biotechnology ETF (IBB 264.52, -2.33) is lower by 0.9%, while the ... More
More Market News
A sustained rally could have important implications for American and multinational companies, potentially resounding across the stock market.
MUST-SEE ON MSN
- Video: Easy DIY smoked meats at home
A charcuterie master shares his process for cold-smoking meat at home.
- Jetpacks about to go mainstream
- Weird things covered by home insurance
- Bing: 70 percent of adults report 'digital eye strain'